Gilead Sciences, Inc. (NASDAQ:GILD) Trade Alert
GILEAD SCI closed down -0.970 at 115.040. Volume was 18% below average (neutral) and Bollinger Bands were 12% wider than normal.
Open High Low Close Volume___
116.330 116.490 114.910 115.040 8,831,970
Technical Outlook
Short Term: Oversold
Intermediate Term: Bearish
Long Term: Bullish
Moving Averages: 10-period 50-period 200-period
Close: 118.88 111.93 104.97
Volatility: 26 27 40
Volume: 10,706,724 11,110,540 13,835,474
Short-term traders should pay closer attention to buy/sell arrows while intermediate/long-term traders should place greater emphasis on the Bullish or Bearish trend reflected in the lower ribbon.
HEFX Candlesticks
A black body occurred (because prices closed lower than they opened).
During the past 10 bars, there have been 3 white candles and 7 black candles for a net of 4 black candles. During the past 50 bars, there have been 30 white candles and 20 black candles for a net of 10 white candles.
Three black candles occurred in the last three days. Although these candles were not big enough to create three black crows, the steady downward pattern is bearish.
Summary
GILEAD SCI is currently 9.6% above its 200-period moving average and is in an downward trend. Volatility is extremely high when compared to the average volatility over the last 10 periods. There is a good possibility that volatility will decrease and prices will stabilize in the near term. Our volume indicators reflect volume flowing into and out of GILD.O at a relatively equal pace (neutral). Our trend forecasting oscillators are currently bearish on GILD.O and have had this outlook for the last 0 periods.
Momentum Indicators
Momentum is a general term used to describe the speed at which prices move over a given time period. Generally, changes in momentum tend to lead to changes in prices. This expert shows the current values of four popular momentum indicators.
Stochastic Oscillator
One method of interpreting the Stochastic Oscillator is looking for overbought areas (above 80) and oversold areas (below 20). The Stochastic Oscillator is 12.4288. This is an oversold reading. However, a signal is not generated until the Oscillator crosses above 20 The last signal was a sell 5 period(s) ago.
Relative Strength Index (RSI)
The RSI shows overbought (above 70) and oversold (below 30) areas. The current value of the RSI is 46.56. This is not a topping or bottoming area. A buy or sell signal is generated when the RSI moves out of an overbought/oversold area. The last signal was a sell 5 period(s) ago.
Commodity Channel Index (CCI)
The CCI shows overbought (above 100) and oversold (below -100) areas. The current value of the CCI is -133.This is an oversold reading. However, a signal isn’t generated until the indicator crosses above -100. The last signal was a buy 2 period(s) ago.
MACD
The Moving Average Convergence/Divergence indicator (MACD) gives signals when it crosses its 9 period signal line. The last signal was a sell 5 period(s) ago.
Gilead Sciences, Inc. (Gilead), incorporated on June 22, 1987, is a research-based biopharmaceutical company that discovers, develops and commercializes innovative medicines. The Company’s primary areas of focus include human immunodeficiency virus (HIV), liver diseases such as chronic hepatitis C virus (HCV) infection and chronic hepatitis B virus (HBV) infection, oncology and inflammation, and serious cardiovascular and respiratory conditions.
HIV
The Company’s HIV products include Stribild, Complera/Eviplera, Atripla, Truvada, Viread, Emtriva, Tybost and Vitekta. Stribild is an oral formulation dosed once a day for the treatment of HIV-1 infection in treatment-naive adults. Stribild is the Company’s third complete single tablet regimen for the treatment of HIV and is a fixed-dose combination of its antiretroviral medications, Vitekta, Tybost, Viread and Emtriva (emtricitabine). Stribild was approved by the United States Food and Drugs Administration (FDA) and the European Commission. Complera/Eviplera is an oral formulation dosed once a day for the treatment of HIV-1 infection in adults. The product is available in the United States as Complera and in Europe as Eviplera, is the Company’s second complete single tablet regimen for the treatment of HIV and is a fixed-dose combination of its antiretroviral medications, Viread and Emtriva, and Janssen’s non-nucleoside reverse transcriptase inhibitor, Edurant (rilpivirine). Atripla is an oral formulation dosed once a day for the treatment of HIV infection in adults. Atripla is its first single tablet regimen for HIV intended as a stand-alone therapy or in combination with other antiretrovirals. It is a fixed-dose combination of the Company’s antiretroviral medications, Viread and Emtriva, and Bristol-Myers Squibb Company’s (BMS’s) non-nucleoside reverse transcriptase inhibitor, Sustiva (efavirenz). Truvada (emtricitabine and tenofovir disoproxil fumarate) is an oral formulation dosed once a day as part of combination therapy to treat HIV infection in adults. It is a fixed-dose combination of its antiretroviral medications, Viread and Emtriva. The FDA also approved Truvada, in combination with safer sex practices, to reduce the risk of sexually acquired HIV-1 infection in adults at high risk; a strategy called pre-exposure prophylaxis (PrEP).
Viread is an oral formulation of a nucleotide analog reverse transcriptase inhibitor, dosed once a day as part of combination therapy to treat HIV infection in patients two years of age and older. The European Commission approved the use of Viread in combination with other antiretroviral agents for the treatment of HIV-1 infected adolescent patients aged two to less than 18 years with nucleoside reverse transcriptase inhibitor resistance or toxicities precluding the use of first-line pediatric agents. Emtriva is an oral formulation of a nucleoside analog reverse transcriptase inhibitor, dosed once a day as part of combination therapy to treat HIV infection in adults. In the United States and Europe, Emtriva is also available as an oral solution approved as part of combination therapy to treat HIV infection in children. Tybost is a pharmacokinetic enhancer dosed once a day that boosts blood levels of certain HIV medicines. Tybost is indicated as a boosting agent for the HIV protease inhibitors atazanavir (300 mg once daily) and darunavir (800 mg once daily) as part of antiretroviral combination therapy in adults with HIV-1 infection. The FDA has approved Tybost, a pharmacokinetic enhancer that boosts blood levels of certain HIV medicines. Vitekta is an oral formulation of an integrase inhibitor, dosed once a day as part of combination therapy to treat HIV infection in adults without known mutations associated with resistance to elvitegravir, the active ingredient of Vitekta. Vitekta is indicated for use as part of HIV treatment regimens that include a ritonavir-boosted protease inhibitor.
The Company has advanced the development of a new single tablet regimen, E/C/F/TAF, for the treatment of HIV-1 infection in adults. Marketing applications for E/C/F/TAF are filed in the United States and European Union. Phase III clinical studies demonstrated that patients taking E/C/F/TAF experienced favorable renal and bone safety compared to Stribild patients. The Company is also conducting Phase II clinical trials of the fixed-dose co-formulation of TAF and emtricitabine. Under an agreement with Janssen R&D Ireland (Janssen), formerly Tibotec Pharmaceuticals, the Company is evaluating a single tablet regimen of TAF, cobicistat, darunavir and emtricitabine for the treatment of HIV infection.
Liver Diseases
The Company liver diseases products include Harvoni, Sovaldi, Viread and Hepsera. Harvoni is an oral formulation of the NS5A inhibitor with a nucleotide analog polymerase inhibitor dosed once a day for the treatment of HCV genotype 1 infection in adults. Harvoni was approved by the FDA and by the European Commission. In Europe, Harvoni is also indicated for certain patients with HCV genotype 4 infection, HCV genotype 3 infection with cirrhosis and/or prior treatment failure and those with HCV/HIV-1 co-infection. Sovaldi is an oral formulation of a nucleotide analog polymerase inhibitor dosed once a day for the treatment of HCV as a component of a combination antiviral treatment regimen. Sovaldi is approved by the FDA and by the European Commission. Sovaldi’s efficacy has been established in patients with HCV genotypes 1, 2, 3 or 4 infection (in United States and Europe) and genotypes 5 and 6 infection (in Europe), including those with hepatocellular carcinoma meeting Milan criteria (awaiting liver transplantation) and those with HCV/HIV-1 co-infection. Viread is an oral formulation of a nucleotide analog reverse transcriptase inhibitor, dosed once a day for the treatment of chronic HBV in adults with compensated and decompensated liver disease. The Company licensed to GlaxoSmithKline Inc. (GSK) the rights to commercialize Viread for the treatment of chronic HBV in China, Japan and Saudi Arabia.The European Commission approved the use of Viread for the treatment of chronic HBV infection in adolescent patients aged 12 to less than 18 years with compensated liver disease and evidence of immune active disease. Hepsera (adefovir dipivoxil) is an oral formulation of a nucleotide analog polymerase inhibitor, dosed once a day to treat chronic HBV in patients 12 years of age and older. The Company licensed to GSK the rights to commercialize Hepsera for the treatment of chronic HBV in Asia Pacific, Latin America and certain other territories.
The Company has filed its marketing applications for sofosbuvir and the fixed-dose combination of ledipasvir and sofosbuvir in Japan. Its fixed-dose combination of sofosbuvir and GS-5816, a pan-genotypic NS5A inhibitor, is being developed an oral therapy in Phase III clinical trials for all hepatitis C virus (HCV) patients across genotypes. The Company is evaluating Tenofovir Alafenamide (TAF) for the treatment of hepatitis B virus (HBV) and has completed enrollment of Phase III clinical trials. It is also conducting Phase II clinical studies of GS-4774, a Tarmogen T cell immunity stimulator, and GS-9620, an oral TLR-7 agonist, being evaluated as a potential cure for HBV.
Oncology
The Company oncology product is Zydelig, which is a first-in-class PI3K delta inhibitor, in combination with rituximab, for the treatment of certain blood cancers. The Company received FDA and European Commission approval of Zydelig (idelalisib), in combination with rituximab, for the treatment of patients with certain blood cancers, such as chronic lymphocytic leukemia (CLL) and follicular lymphoma (FL). The Company is conducting Phase III clinical studies to evaluate idelalisib as a treatment for patients with Indolent non-Hodgkin lymphoma (iNHL) and a frontline treatment for patients with CLL.
Cardiovascular
The Company’s cardiovascular products include Letairis, Ranexa and Lexiscan/Rapiscan. Letairis (ambrisentan) is an oral formulation of an endothelin receptor antagonist (ERA) indicated for the treatment of pulmonary arterial hypertension (PAH) in patients with WHO Class II or III symptoms to improve exercise capacity and delay clinical worsening. It sublicensed to GSK the rights to ambrisentan, marketed by GSK as Volibris (ambrisentan), for PAH in territories outside of the United States. Ranexa (ranolazine) is an extended-release tablet for the treatment of chronic angina. The Company has licensed to Menarini International Operations Luxembourg SA the rights to Ranexa in territories outside of the United States. Lexiscan/Rapiscan (regadenoson) injection is indicated for use as a pharmacologic stress agent in radionuclide myocardial perfusion imaging (MPI), a test that detects and characterizes coronary artery disease, in patients unable to undergo adequate exercise stress. Astellas US LLC (Astellas) has exclusive rights to manufacture and sell regadenoson under the name Lexiscan in the United States. Rapidscan Pharma Solutions, Inc. (RPS) holds the exclusive right to manufacture and sell regadenoson under the name Rapiscan in Europe and certain territories outside the United States. The Company receives royalties from Astellas and RPS for sales in these territories.
The Company has conducted an AMBITION study (a randomized, double-blind, multicenter study of first-line combination therapy with Letairis (ambrisentan) and tadalafil in patients with pulmonary arterial hypertension), in collaboration with GlaxoSmithKline plc which demonstrated positive results. In AMBITION, first-line treatment of pulmonary arterial hypertension with the combination of ambrisentan 10 milligram (mg) and tadalafil 40 mg reduced the risk of clinical failure by 50% compared to the pooled ambrisentan and tadalafil monotherapy arm. The combination was also statistically significant versus the individual ambrisentan and tadalafil monotherapy groups for the primary endpoint. The Company has filed a supplemental new drug application (NDA) in the United States to cover the use of ambrisentan in combination with tadalafil.
Respiratory
The Company’s respiratory products include Cayston and Tamiflu. Cayston (aztreonam for inhalation solution) is an inhaled antibiotic for the treatment of respiratory systems in cystic fibrosis (CF) patients seven years of age and older with Pseudomonas aeruginosa (P. aeruginosa). Tamiflu (oseltamivir phosphate) is an oral antiviral available in capsule form for the treatment and prevention of influenza A and B. Tamiflu is approved for the treatment of influenza in children and adults in more than 60 countries, including the United States, Japan and the European Union. Tamiflu is also approved for the prevention of influenza in children and adults in the United States, Japan and the European Union. The Company developed Tamiflu with F. Hoffmann-La Roche Ltd (together with Hoffmann-La Roche Inc., Roche). Roche has the exclusive right to manufacture and sell Tamiflu worldwide.
Other
The Company’s products under the Other products include AmBisome and Macugen. AmBisome (amphotericin B liposome for injection) is a liposomal formulation of amphotericin B, an antifungal agent to treat serious invasive fungal infections caused by various fungal species in adults. Its corporate partner, Astellas Pharma US, Inc., promotes and sells AmBisome in the United States and Canada, and the Company promotes and sells AmBisome in Europe, Australia and New Zealand. Macugen (pegaptanib sodium injection) is an intravitreal injection of an anti-angiogenic oligonucleotide for the treatment of neovascular age-related macular degeneration. Macugen is promoted in the United States by Valeant Pharmaceuticals, Inc. (Valeant). Valeant holds the exclusive rights to manufacture and sell Macugen in the United States, and Pfizer Inc. (Pfizer) holds the exclusive right to manufacture and sell Macugen in the rest of the world. The Company receives royalties from Valeant and Pfizer based on worldwide sales of Macugen.
The Company competes with ViiV Healthcare, AbbVie Inc., Boehringer Ingelheim GmbH, Merck, Roche, Janssen, GSK, Bristol-Myers Squibb, Novartis Pharmaceuticals Corporation, Shire plc., Actelion Pharmaceuticals US, Inc., United Therapeutics Corporation, BioCryst Pharmaceuticals, Inc., Pharmacyclics, Inc., Pfizer, Enzon Pharmaceuticals, Inc., Three Rivers Pharmaceuticals, LLC, Zeneus Pharma Ltd., Genpharma, S.A. and Genentech, Inc.
The post Gilead Sciences, Inc. (NASDAQ:GILD) Trade Alert appeared first on Live Trading News.